Co-administration of resveratrol with doxorubicin in young mice attenuates detrimental late-occurring cardiovascular changes

ConclusionWe have developed a juvenile mouse model of DOX-induced cardiotoxicity that displays no immediate overt physiological dysfunction; but, leads to an impaired ability of the heart to adapt to hypertension later in life. We also show that co-administration of resveratrol during DOX treatment was sufficient to normalize molecular markers of cardiotoxicity and restore the ability of the heart to undergo adaptive remodelling in response to hypertension later in life.
Source: Cardiovascular Research - Category: Cardiology Source Type: research